Hyphens Pharma International Limited Stock

Equities

1J5

SG1EE4000006

Pharmaceuticals

Delayed Singapore S.E. 11:36:46 2024-04-24 pm EDT 5-day change 1st Jan Change
0.275 SGD 0.00% Intraday chart for Hyphens Pharma International Limited 0.00% -3.51%
Sales 2024 * 183M 135M Sales 2025 * 192M 141M Capitalization 84.9M 62.48M
Net income 2024 * 11M 8.09M Net income 2025 * 12M 8.83M EV / Sales 2024 * 0.46 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.44 x
P/E ratio 2024 *
7.65 x
P/E ratio 2025 *
7.08 x
Employees 431
Yield 2024 *
3.85%
Yield 2025 *
4.05%
Free-Float 18.14%
More Fundamentals * Assessed data
Dynamic Chart
Current month+3.77%
1 month-3.51%
3 months-1.79%
6 months-1.79%
Current year-3.51%
More quotes
1 week
0.27
Extreme 0.27
0.28
1 month
0.27
Extreme 0.265
0.29
Current year
0.27
Extreme 0.265
0.31
1 year
0.27
Extreme 0.265
0.35
3 years
0.27
Extreme 0.265
0.38
5 years
0.18
Extreme 0.18
0.63
10 years
0.16
Extreme 0.16
0.63
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 97-12-31
Director of Finance/CFO - 22-12-31
Chief Operating Officer 59 19-08-31
Members of the board TitleAgeSince
Director/Board Member 59 18-04-22
Director/Board Member 52 20-11-04
Chief Executive Officer 56 97-12-31
More insiders
Date Price Change Volume
24-04-25 0.275 0.00% 57,000
24-04-24 0.275 0.00% 39,900
24-04-23 0.275 0.00% 40,000
24-04-22 0.275 +1.85% 23,700
24-04-19 0.27 -1.82% 105,000

Delayed Quote Singapore S.E., April 24, 2024 at 11:36 pm EDT

More quotes
Hyphens Pharma International Limited is a Singapore-based specialty pharmaceutical and consumer healthcare company. The Company's principal activities are those of an investment holding company and provision of management services. The Company's segments include Specialty pharma principals, Proprietary brands, and Medical hypermart and digital. The Specialty pharma principals segment is engaged in the business of marketing and selling a range of specialty pharmaceutical products with exclusivity in the relevant ASEAN countries. The Proprietary brands segment is engaged in the business of developing, marketing and selling its own proprietary range of dermatological products and health supplement products. The Medical hypermart and digital segment is a wholesaler of pharmaceuticals and medical supplies in Singapore, which the Company and its subsidiaries position themselves as a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.275 SGD
Average target price
0.35 SGD
Spread / Average Target
+27.27%
Consensus

Annual profits - Rate of surprise